Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Taysha Gene Therapies announced new preclinical data demonstrating that their TSHA-102 gene therapy, based on self-complementary AAV9 delivering a miniaturized MECP2 transgene, achieves approximately 30-fold higher MeCP2 protein expression compared to a single-stranded AAV9 construct in neuronal models. These results validate the design of TSHA-102…